{
  "content": "Diagnosis\n\t1. Extensive stage large cell neuroendocrine carcinoma of lung with liver and bone metastases\n\n\tDate of diagnosis\n\tJanuary 2024\n\n\tTreatment aim\n\tPalliative - Disease control\n\n\tSummary of completed treatment and relevant dates\n\n\tSurgery\n\tNot indicated\n\n\tRadiotherapy\n\t15 Feb 2024 Palliative radiotherapy to T7 vertebral metastasis\n\n\tChemotherapy\n\tCarboplatin/Etoposide completed 4 cycles March 2024 with partial response\n\n\tClinical studies\n\tIMPACT-NE trial registration completed today\n\n\tCurrent disease status\n\tPartial response to first line therapy. Now eligible for trial participation.\n\n\tCurrent issues\n\tMild peripheral neuropathy from previous chemotherapy\n\n\tSummary of consultation\n\tThis 58-year-old gentleman has shown good partial response to initial carboplatin/etoposide with reduction in liver metastases and improvement in bone pain. Performance status has improved from 2 to 1. Molecular testing confirms RB1 and TP53 loss. All eligibility criteria for IMPACT-NE trial have been met including adequate organ function and resolution of previous grade 2 thrombocytopenia.\n\nTrial procedures completed today include baseline CT chest/abdomen/pelvis, ECG, echocardiogram, and required blood tests. Patient has signed informed consent after detailed discussion of trial requirements, risks, and benefits. Randomization completed - allocated to experimental arm (AMG 123 + SOC).\n\n\tFurther investigations\n\tBaseline brain MRI scheduled 25 April 2024\n\n\tMedication prescribed\n\tTrial medication to commence 29 April 2024 pending brain MRI\n\n\tFollow up\n\tTrial assessment clinic in 2 weeks\n\tCycle 1 Day 1 scheduled for 29 April 2024\n\n\tRequired GP actions\n\tWeekly FBC, U&E, LFT monitoring as per trial protocol\n\n\tSummary of information given to patient\n\tProvided with trial emergency card, medication diary, and 24-hour contact numbers. Advised regarding required frequency of hospital visits and monitoring requirements.",
  "output": {
    "primary_cancer": {
      "site": "lung, diffuse",
      "year": 2024,
      "month": 1,
      "metastases": "liver and bone metastases",
      "histopathology_status": "large cell neuroendocrine carcinoma",
      "biomarker_status": "RB1 and TP53 loss",
      "cancer_timeline": [
        {
          "type": "treatment_systemic_start",
          "value": "Started Carboplatin/Etoposide chemotherapy",
          "year": 2024,
          "month": 2
        },
        {
          "type": "treatment_radiotherapy",
          "value": "Palliative radiotherapy to T7 vertebral metastasis",
          "year": 2024,
          "month": 2
        },
        {
          "type": "treatment_systemic_change",
          "value": "Completed 4 cycles Carboplatin/Etoposide with partial response",
          "year": 2024,
          "month": 3
        },
        {
          "type": "clinical_trial_update",
          "value": "Enrolled in IMPACT-NE trial, randomized to experimental arm (AMG 123 + SOC)",
          "year": 2024,
          "month": 4
        }
      ]
    },
    "patient_facts": [
      {
        "type": "performance_status",
        "value": "Performance status improved from 2 to 1"
      },
      {
        "type": "current_symptom",
        "value": "Mild peripheral neuropathy from previous chemotherapy"
      },
      {
        "type": "investigation_finding",
        "value": "Adequate organ function confirmed on baseline testing"
      }
    ],
    "status_updates": [
      {
        "type": "clinical_summary",
        "value": "Extensive stage neuroendocrine lung cancer showing partial response to first-line chemotherapy. Now enrolled in IMPACT-NE trial."
      },
      {
        "type": "latest_treatment_response",
        "value": "Partial response with reduction in liver metastases and improvement in bone pain"
      },
      {
        "type": "latest_treatment_toxicity",
        "value": "Previous grade 2 thrombocytopenia now resolved"
      },
      {
        "type": "update_to_treatment",
        "value": "Randomized to experimental arm of IMPACT-NE trial (AMG 123 + SOC)"
      },
      {
        "type": "planned_investigation",
        "value": "Baseline brain MRI scheduled 25 April 2024"
      },
      {
        "type": "follow_up_referral",
        "value": "Trial assessment clinic in 2 weeks, Cycle 1 Day 1 scheduled for 29 April 2024"
      }
    ]
  }
}